NCT03477487View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 8, 2018

Primary Completion Date

July 19, 2019

Study Completion Date

September 30, 2019

Conditions
Osteoarthritis, Knee
Interventions
BIOLOGICAL

XT-150

Human IL-10 variant transgene in a plasmid DNA vector

Trial Locations (1)

94558

Neurovations (Napa Pain Institute), Napa

All Listed Sponsors
lead

Xalud Therapeutics, Inc.

INDUSTRY

NCT03477487 - Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain | Biotech Hunter | Biotech Hunter